Assessment of LBR-101 In Chronic Migraine

Two distinct doses of subcutaneous LBR-101 administered monthly will be compared to placebo
for safety and efficacy. The mean change from baseline in the number of cumulative headache
hours measured at the 28-day period ending with week 12.

Inclusion Criteria:

- Males or females aged 18 to 65 years of age.

- A signed and dated informed consent document indicating that the subject has been
informed of all pertinent aspects of the study including any known and potential risks
and available alternative treatments.

- Chronic migraine meeting the diagnostic criteria listed in the International
Classification of Headache Disorders (ICHD-III beta version, 2013)

- Body Mass Index (BMI) of 17.5 to 37.5 kg/m2, and a total body weight between 50 kg and
120 kg inclusive.

- Demonstrated compliance with the electronic headache diary during the run-in period
headache data on a minimum of 22/28 days (80% diary compliance)

Exclusion Criteria:

- Onset of chronic migraine after the age of 50 years.

- Subject has received onabotulinum toxin A for migraine or for any medical or cosmetic
reasons requiring injections in the head, face, or neck during the 6 months prior to
study entry.

- Subject is using medications containing opioids (including codeine) or barbiturates
(including Fiorinal®, Fioricet®, or any other combination containing butalbital) on
more than 4 days per month for the treatment of migraine or for any other reason.

- Failed > 2 medication categories or > 3 preventive medications (within two medication
categories) due to lack of efficacy for prophylactic treatment of episodic or chronic
migraine after an adequate therapeutic trial

- Treatment with an investigational drug or device within 30 days of study entry or any
prior exposure to a monoclonal antibody targeting the CGRP pathway.